Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
Ratios
10 Sheets · Starting from 2022Margins, Growth Rates In %
| Ratio | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | -369.13 | 100.00 | 100.00 | 100.00 | |
| Profit Margin | -68.56 | 1.33 | -2.88 | -12.49 | -99.19 | -150.30 | -1,094.28 | -2,747.00 | -2,588.22 | -14,074.95 | |
| Operating Margin | -20.35 | 6.89 | -0.73 | -14.23 | -97.62 | -143.46 | -1,075.61 | -2,509.42 | -2,129.75 | -12,191.11 | |
|
EPS Growth
|
- - | 102.04 | -300.00 | -19.23 | -541.94 | -46.23 | -227.84 | 22.96 | -11.43 | -4.88 | |
| EPS USD | -638.00 | 13.00 | -26.00 | -31.00 | -199.00 | -291.00 | -954.00 | -735.00 | -819.00 | -859.00 | |
| Return on Assets (ROA) | -15.30 | 0.55 | -1.84 | -6.99 | -35.22 | -23.33 | -42.52 | -28.89 | -40.46 | -60.62 | |
| Return on Equity (ROE) | 12.67 | -0.25 | 0.53 | 2.15 | 14.14 | 19.16 | 40.84 | 25.85 | 23.68 | 474.77 | |
| Return on Invested Capital (ROIC) | 16.20 | -0.25 | 0.65 | 2.34 | 14.78 | 23.61 | 74.73 | 23.83 | 24.92 | -155.94 | |
| Solvency | |||||||||||
| Equity Ratio | -100 | -200 | -300 | -300 | -200 | -100 | -100 | -100 | -100 | - - | |
| Debt/Assets | 25.65 | 3.84 | 4.47 | 6.90 | 14.49 | 27.41 | 48.18 | 10.20 | 18.94 | 23.22 | |
| Debt/Equity | -21.24 | -1.76 | -1.29 | -2.13 | -5.82 | -22.52 | -46.28 | -9.13 | -11.08 | -181.85 | |
| Debt/EBITDA | 2,356.52 | -1,440.07 | -2,891.12 | 1,321.05 | 237.03 | 338.24 | 179.15 | 363.32 | 186.54 | -28.68 | |
|
Debt/Capitalization
|
-26.97 | -1.79 | -1.31 | -2.17 | -6.18 | -29.06 | -86.14 | -10.04 | -12.47 | 222.18 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | -5.77 | -23.22 | -27.91 | - - | -12.15 | 227.27 | |
| Interest Debt per Share USD | 10.70 | 0.88 | 0.64 | 0.31 | 0.88 | 3.64 | 11.18 | 3.69 | 5.30 | 4.44 | |
| Debt Growth | - - | - - | - - | - - | - - | 303.89 | 95.68 | -100.00 | - - | -12.18 | |
| Liquidity | |||||||||||
| Current Ratio | 167.14 | 183.66 | 127.03 | 146.37 | 279.54 | 612.08 | 348.56 | 710.84 | 1,104.71 | 674.64 | |
| Quick Ratio | 162.91 | 177.29 | 121.56 | 142.09 | 272.55 | 604.06 | 345.98 | 705.00 | 1,093.19 | 657.25 | |
| Cash Ratio | 153.43 | 151.05 | 69.07 | 142.09 | 272.55 | 604.06 | 345.98 | 686.36 | 1,093.19 | 71.76 | |
| Operating Cash Flow Ratio | - - | -100 | - - | - - | -100 | -100 | -100 | -200 | -400 | -300 | |
| Turnover | |||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | 469.51 | 340.84 | 157.61 | - - | - - | - - | - - | 40.58 | - - | - - | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | 6,519.81 | - - | - - | - - | |
|
Asset Turnover
|
22.31 | 41.36 | 63.73 | 55.96 | 35.51 | 15.52 | 3.89 | 1.05 | 1.56 | 0.43 | |
| Fixed Turnover | 1,033.09 | 2,064.94 | 4,406.22 | 6,087.42 | 6,693.31 | 3,708.58 | 885.08 | 183.61 | 8.30 | 1.90 | |
| Coverage | |||||||||||
| Interest Coverage | - - | - - | - - | - - | -3,226.62 | -1,244.79 | -2,547.29 | -615.36 | -459.54 | -646.75 | |
| Asset Coverage | - - | - - | - - | - - | 400 | 300 | 400 | - - | 500 | 300 | |
| Cash Flow Coverage (CFGR) | -117.16 | -1,839.18 | -1,264.38 | -313.10 | -424.47 | -88.53 | -76.39 | -368.56 | -169.36 | -170.99 | |
| EBITDA Coverage | - - | - - | - - | - - | -3,100 | -1,200 | -2,500 | -600 | -400 | -600 | |
| Dividend Coverage | 7,600 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | 100 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||||
| Dividend Yield | 0.64 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -48.84 | 0.96 | -2.02 | -1.44 | -7.03 | -5.18 | -4.67 | -5.95 | -31.05 | -22.60 | |
|
Price/Earnings (P/E)
|
-204.77 | 10,433.24 | -4,957.59 | -6,947.12 | -1,421.81 | -1,929.42 | -2,142.74 | -1,681.99 | -322.07 | -442.40 | |
| Price/Earnings Growth (PEG) | - - | -102.25 | 16.53 | -361.25 | -2.62 | -41.73 | -9.40 | 73.27 | -28.18 | -90.58 | |
|
Price/Book (P/B)
|
-25.95 | -26.21 | -26.32 | -149.50 | -201.04 | -369.73 | -875.11 | -434.87 | -76.28 | -2,100.39 | |
| Price/Tangible Book (P/TB) | -25.95 | -26.21 | -26.32 | -149.50 | -201.04 | -369.73 | -875.11 | -434.87 | -76.28 | -2,100.39 | |
| Price/Sales (P/S) | 140.40 | 138.36 | 142.86 | 867.69 | 1,410.36 | 2,899.98 | 23,447.51 | 46,204.30 | 8,335.89 | 62,267.51 | |
|
Price/Cash Flow (P/CF)
|
-104.26 | -81.11 | -161.10 | -2,246.21 | -814.11 | -1,854.88 | -2,475.63 | -1,292.79 | -406.36 | -675.51 | |
| Price/Free CF (P/FCF) | -103.77 | -80.94 | -160.13 | -2,207.24 | -810.76 | -1,839.96 | -2,449.56 | -1,289.08 | -404.08 | -664.87 | |
| Price/Operating CF (P/OCF) | -104.26 | -81.11 | -161.10 | -2,246.21 | -814.11 | -1,854.88 | -2,475.63 | -1,292.79 | -406.36 | -675.51 |